Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis

13 Nov 2015

Abstract excerpt

KRAS-activating mutations drive human non-small cell lung cancer and initiate lung tumorigenesis in genetically engineered mouse (GEM) models. However, in a GEM model of KRAS(G12D)-induced lung cancer, tumors arise stochastically following a latency period, suggesting that additional events are required to promote early-stage tumorigenic expansion of KRAS(G12D)-mutated cells. PI3Kα (PIK3CA) is a direct effector...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26567140
DOI: 10.1158/0008-5472.can-15-1249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung TumorigenesisPMID 26567140Read ↗

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Semantic proximity Read ↗

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancerSemantic proximity Read ↗

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.Semantic proximity Read ↗

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity Read ↗

The genetics and biology of KRAS in lung cancer.Semantic proximity Read ↗

An <i>in vivo</i> KRAS allelic series reveals distinct phenotypes of common oncogenic variantsSemantic proximity Read ↗

An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants.Semantic proximity Read ↗

Loss of PIK3CA Allows In Vitro Growth but Not In Vivo Progression of KRAS Mutant Lung Adenocarcinoma in a Syngeneic Orthotopic Implantation Model.Semantic proximity Read ↗

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinaseSemantic proximity Read ↗

Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesisSemantic proximity Read ↗

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilitiesSemantic proximity Read ↗

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.